Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CHAMPIONS ONCOLOGY, INC.

(CSBR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/24/2022 01/25/2022 01/26/2022 01/27/2022 01/28/2022 Date
7.8143(c) 7.75(c) 7.75(c) 7.98(c) 7.8 Last
27 824 2 736 5 525 1 613 11 041 Volume
-2.08% -0.82% 0.00% +2.97% -2.26% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 48,3 M - -
Net income 2022 0,96 M - -
Net Debt 2022 - - -
P/E ratio 2022 120x
Yield 2022 -
Sales 2023 56,4 M - -
Net income 2023 2,97 M - -
Net Debt 2023 - - -
P/E ratio 2023 39,0x
Yield 2023 -
Capitalization 105 M 105 M -
Capi. / Sales 2022 2,18x
Capi. / Sales 2023 1,87x
Nbr of Employees -
Free-Float 70,7%
More Financials
Company
Champions Oncology, Inc. is engaged in creating transformative technology solutions to be utilized in oncology drug discovery and development. This technology includes the CompanyÔÇÖs in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The CompanyÔÇÖs TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and... 
More about the company
Ratings of Champions Oncology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about CHAMPIONS ONCOLOGY, INC.
01/20Champions Oncology Working With Fannin Innovation to Develop Tumor-Specific Therapies
MT
01/20CHAMPIONS ONCOLOGY : Announces a Partnership with Fannin Innovation to Jointly Develop The..
PU
01/04Champions Oncology Working With Alloy Therapeutics to Develop Monoclonal Antibodies for..
MT
2021CHAMPIONS ONCOLOGY : Reports Quarterly Revenue of $11.8 Million
PU
2021CHAMPIONS ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
2021Champions Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months..
CI
2021Champions Oncology Fiscal Q2 Earnings, Revenue Rise
MT
2021Earnings Flash (CSBR) CHAMPIONS ONCOLOGY Reports Q2 EPS $0.03, vs. Street Est of $0.02
MT
2021CHAMPIONS ONCOLOGY : Reports Record Quarterly Revenue of $11.8 Million - Form 8-K
PU
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
2021CHAMPIONS ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021CHAMPIONS ONCOLOGY : Opens European Laboratory in Italy
MT
2021CHAMPIONS ONCOLOGY : Champions Oncology, Inc.
AQ
2021CHAMPIONS ONCOLOGY : Expands Global Biomarker Capabilities with Opening of European Labora..
PU
2021Champions Oncology Expands Global Biomarker Capabilities with Opening of European Labor..
CI
More news
News in other languages on CHAMPIONS ONCOLOGY, INC.
01/20Champions Oncology collabore avec Fannin Innovation pour développer des thérapies spéci..
01/04Champions Oncology collabore avec Alloy Therapeutics pour développer des anticorps mono..
2021CHAMPIONS ONCOLOGY : hausse des revenus et des bénéfices au deuxième trimestre fiscal
2021Champions Oncology ouvre un laboratoire européen en Italie
2021Champions Oncology, Inc. fournit des prévisions de revenus pour l'année fiscale 2022
More news
Analyst Recommendations on CHAMPIONS ONCOLOGY, INC.
More recommendations
Chart CHAMPIONS ONCOLOGY, INC.
Duration : Period :
Champions Oncology, Inc. Technical Analysis Chart | CSBR | US15870P3073 | MarketScreener
Technical analysis trends CHAMPIONS ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 7,80 $
Average target price 15,67 $
Spread / Average Target 101%
EPS Revisions
Managers and Directors
Ronnie Morris President Chief Executive Officer & Director
David Barry Miller Chief Financial Officer
Joel Ackerman Chairman
Karin Abarca Heidemann Vice President-Scientific Operations
David Sidransky Director
Sector and Competitors
1st jan.Capi. (M$)
CHAMPIONS ONCOLOGY, INC.-4.55%108
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892